3-硝基-4-甲基苯乙酮 | 5333-27-7

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-硝基-4-甲基苯乙酮
• 中文别名: 4’-甲基-3’-硝基苯乙酮；4'-甲基-3'-硝基苯乙酮；3'-硝基-4'-甲基苯乙酮
• 英文名称: 1-(4-methyl-3-nitro-phenyl)-ethanone
• 英文别名: 1-(4-methyl-3-nitrophenyl)ethan-1-one；3-Nitro-4-methyl-acetophenon；3-nitro-4-methylacetophenone；4-methyl-3-nitroacetophenone；2-Methyl-5-acetyl-nitrobenzol；1-(4-Methyl-3-nitrophenyl)ethanone
• CAS: 5333-27-7
• 化学式: C₉H₉NO₃
• mdl: MFCD00033858
• 分子量: 179.175
• InChiKey: YRBBMDOBWRUMEZ-UHFFFAOYSA-N

物化性质

• 熔点：
  57-61 °C
• 沸点：
  256.4±20.0 °C(Predicted)
• 密度：
  1.201±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2914700090
• 安全说明：
  S26,S37/39
• 储存条件：
  避光，存放在阴凉、干燥的地方，并密封保存。

SDS

Name:	3-Nitro-4-Methylacetophenone Material Safety Data Sheet
Synonym:	None Known
CAS:	5333-27-7

Section 1 - Chemical Product MSDS Name:3-Nitro-4-Methylacetophenone Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5333-27-7	3-Nitro-4-Methylacetophenone	ca. 100	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5333-27-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H9NO3
Molecular Weight: 179.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5333-27-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Nitro-4-Methylacetophenone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 5333-27-7: No information available.
Canada
CAS# 5333-27-7 is listed on Canada's NDSL List.
CAS# 5333-27-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5333-27-7 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-硝基-4-甲基苯乙酮 在 盐酸 、 硝酸 、 锌 作用下， 生成 acetic acid-(3-ethyl-6-methyl-2,4-dinitro-anilide)
  参考文献：
  名称：

  31.烷基苯的硝化。第一部分：对乙基甲苯的硝化

  摘要：

  DOI：

  10.1039/jr9340000114
• 作为产物：
  描述：

  对甲基苯乙酮 在 硫酸 、 硝酸胍 作用下， 反应 3.0h， 以85%的产率得到3-硝基-4-甲基苯乙酮
  参考文献：
  名称：

  通过甲基转移酶催化的转移和光触发的光笼基团的去除可逆地修饰DNA

  摘要：

  甲基转移酶是从其共底物S-腺苷-L-甲硫氨酸（AdoMet）的合成类似物中非天然官能团进行位点特异性转移的有力工具。我们提出了一类新的AdoMet类似物，在其侧链中包含光笼（PC）基团，通过混杂DNA MTase酶促转移PC基团，以及从目标DNA触发光触发去除。该策略提供了一条新途径，可逆地调节MTase靶位点DNA的功能。

  DOI：

  10.1039/c7cc08300a
• 作为试剂：
  描述：

  硫酸 、 对甲基苯乙酮 、 硝酸 在 ice 、 水 、 二氯甲烷 、 碳酸氢钠 、 氯化钠 、 正己烷 、 3-硝基-4-甲基苯乙酮 作用下， 反应 1.17h， 生成 3-硝基-4-甲基苯乙酮
  参考文献：
  名称：

  Anovulatory method and chicken feed compositions

  摘要：

  2-(取代苯基亚胺基)咪唑啉可以延迟幼鸡的产蛋时间并打断成熟母鸡的产蛋，因此在人工引发蜕羽期中是有用的。

  公开号：

  US04287201A1

文献信息

• THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
  申请人：Nakao Akira

  公开号：US20120196824A1

  公开（公告）日：2012-08-02

  The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

  这项发明提供了一种用于缺血性中风的治疗药物。该治疗药物具有如下式（I）的化学式，其中每个符号如本文所定义，或其药理学上可接受的盐，或其溶剂化物，作为活性成分。
• Anti-Viral Compounds
  申请人：DeGoey David A.

  公开号：US20100317568A1

  公开（公告）日：2010-12-16

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法、包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。
• Rhodium(III)-Catalyzed Oxidative Annulation of Ketoximes with Sulfonamide: A Direct Approach to Indazoles
  作者：Ning Wang、Lingling Liu、Wentao Xu、Mengye Zhang、Zhibin Huang、Daqing Shi、Yingsheng Zhao

  DOI：10.1021/acs.orglett.8b03488

  日期：2019.1.18

  A rhodium(III)-catalyzed intermolecular C–H amination of ketoxime and iodobenzene diacetate-enabled N–N bond formation in the synthesis of indazoles has been developed. A variety of functional groups were well tolerated, providing the corresponding products in moderate to good yields. Moreover, the nitro-substituted ketoximes are well compatible in this reaction, leading to the corresponding products

  在吲哚合成中，铑（III）催化了酮肟的分子间CH-H胺化反应和碘代苯二乙酸酯使N-N键形成。各种官能团的耐受性良好，可提供中等至良好收率的相应产物。此外，硝基取代的酮肟在该反应中具有良好的相容性，从而以中等至良好的收率得到相应的产物。
• Radical Trifluoromethoxylation of Arenes Triggered by a Visible‐Light‐Mediated N−O Bond Redox Fragmentation
  作者：Benson J. Jelier、Pascal F. Tripet、Ewa Pietrasiak、Ivan Franzoni、Gunnar Jeschke、Antonio Togni

  DOI：10.1002/anie.201806296

  日期：2018.10.15

  method enables non‐directed functionalization of C−H bonds on a range of substrates, providing access to aryl trifluoromethyl ethers. This light‐driven process is distinctly different from conventional procedures and occurs through an OCF3 radical mechanism mediated by a photoredox catalyst, which triggers an N−O bond fragmentation. The pyridinium‐based trifluoromethoxylation reagent is bench‐stable and

  一种简单的三氟甲氧基化方法可以在一系列底物上实现CH键的非定向功能化，从而可以使用芳基三氟甲基醚。这种光驱过程与传统方法有明显不同，它是通过光氧化还原催化剂介导的OCF 3自由基机理发生的，该机理引发了N-O键断裂。基于吡啶鎓的三氟甲氧基化试剂具有台式稳定性，可通过操作简单的方式获得铅化合物的合成多样性。
• [EN] 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHÉNYLIMIDAZO[1,2-A]PYRIDINE, ET 2-PHÉNYLIMIDAZO[1,2-A]PYRAZINE
  申请人：PAMLICO PHARMACEUTICAL INC

  公开号：WO2012088411A1

  公开（公告）日：2012-06-28

  Disclosed are compounds of formula (I): (Formula (I) where X, Y, X, A, R1; R2, and R3 are defined herein. Also disclosed are pharmaceutically acceptable salts of the compounds, compositions containing the compounds, and methods of using the compounds to treat, e.g., cancer.

  公开的是式(I)的化合物：（式(I)中X、Y、X、A、R1、R2和R3的定义如本文所述。还公开了这些化合物的药用盐、含有这些化合物的组合物，以及使用这些化合物治疗癌症等疾病的方法。